Comparing adalimumab biosimilars in the clinical practice of psoriatic patients
The findings of this study support the efficacy and safety of Idacio and Imraldi in managing psoriasis, with Idacio demonstrating superior efficacy in reducing disease severity. Future studies could benefit from expanding the patient cohort and conducting further analyses to evaluate individual responses to treatment.
Authors
- Federica Rega
- Flavia Persechino (ORCID: https://orcid.org/0000-0001-7476-0326)
- Antonio Di Guardo (ORCID: https://orcid.org/0000-0002-0117-346X)
- Nazareno Gagliostro (ORCID: https://orcid.org/0000-0002-6419-9851)
- Andrea Vizzaccaro
- Giulia Maretti (ORCID: https://orcid.org/0009-0009-7626-5447)
- Domenico Giordano (ORCID: https://orcid.org/0000-0003-0624-2097)
- Severino Persechino (ORCID: https://orcid.org/0000-0002-3728-5877)
- Annamaria Larosa
Institutions
- Policlinico Umberto I (IT)
Publication Details
- Journal
- Italian Journal of Dermatology and Venereology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.23736/s2784-8671.24.07914-3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00